CALQUENCE® (Acalabrutinib) with VENCLEXTA® (Venetoclax)

The FDA on February 19, 2026, approved CALQUENCE® tablets and capsules in combination with VENCLEXTA® for adults with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). CALQUENCE® is a product of AstraZeneca and VENCLEXTA® is a product of AbbVie Inc. and Genentech Inc.